Skip to main content

Chair Roger Van Geen – Lecture series 2026

Laureate lectures by Prof. Carine Michiels

MICHIELS_Carine_BBrolet.jpg

Inaugural lecture | How cell biology and radiation physics met to boost radiotherapy

30/6/2026

Among the various available anti-cancer therapeutic options, radiotherapy (RT) remains a cornerstone, as highlighted by the fact that more than 50% of patients receive such a treatment. Indeed, RT is used either as a curative approach for localized tumors, as an adjuvant therapy to prevent relapse after surgery, or as a palliative treatment for metastatic disease. Although conventional X-ray RT is widely used in clinics due to their moderate cost and the numerous facilities available, several drawbacks need to be highlighted. Recently, a growing interest for charged particle (protons, carbon ions and alpha particles) RT emerged, as they harbor unique physical and biological characteristics opening new avenues for cancer treatment.

The inaugural lecture of the Chair Roger Van Geen will be devoted to describing how radiotherapy induces cancer cell killing and tumor control. In the framework of C. Michiels’ research, a particular interest relies on the comparison of the effects of X-ray RT vs RT using charged particles, including protons and alpha particles. For instance, the responses of different types of cancer cells as well as cell the adaptation of the tumor microenvironment after exposure to different radiation modalities as well as to chemotherapy have been investigated.

The deciphering of the pathways of cell responses to different types of radiations, both in vitro and in vivo, aims at boosting the effects of anti-cancer radiotherapy and developing new strategies to improve patient care.

Hypoxia induces cancer resistance to chemo- and radio-therapies

22/09/2026

Important contributions of the Michiels’ team are the better understanding the cell responses to hypoxia, notably the ones involving gene expression regulation and the study of the effects of hypoxia on cancer cell survival. These responses allow cancer cells to survive the hypoxic conditions developing in the tumor microenvironment but also to become resistant to chemotherapy. For example, the team has shown that hypoxia protects cancer cells from the apoptosis induced by etoposide or paclitaxel. Invalidation studies using siRNA evidenced that the transcription factor HIF-1 is a major regulator of this resistance. In addition, hypoxia also inhibits p53 activation, thus preventing apoptosis to be initiated. Finally, the group has also shown that etoposide also induces autophagy that participates to cell death under normoxia but not under hypoxia, probably through a different regulation of BNIP3 expression and/or function and via JNK activation. Since then, hypoxia is now recognized as a major factor involved in cancer chemoresistance.

Through a whole genome transcriptomic approach, Michiels’ team discovered TMEM45A as a new gene, induced by hypoxia, responsible for cancer cell resistance. TMEM45A is a transmembrane protein whose expression is correlated to a low cancer patient overall survival. Using head and neck squamous cell carcinoma and renal cell carcinoma biopsies, it was shown that TMEM45A is upregulated in the tumors when compared to the corresponding adjacent healthy tissues. TMEM45A inactivation decreased cell proliferation and modulated cell responses to several chemotherapeutic drugs. Through RNA-sequencing analysis, several dysregulated pathways were identified that indicated that the impact on drug sensitivity may be associated to the inhibition of DNA damage repair and to UPR pathway activation. This study highlighted the role of TMEM45A in modulating cancer cell responses to treatment.

In addition to inducing chemoresistance, hypoxia also modulates cell responses to radiotherapy and initiates a pro-inflammatory feedback loop maintaining endothelial cell and macrophage activation.

In conclusion, hypoxia via these different processes is a major cancer hallmark involved in tumor growth and aggressiveness.

The use of nanoparticles as enhancers for radiotherapy: promises and limits

06/10/2026

The use of charged particle radiation therapy in combination with gold nanoparticles (AuNPs) is of particular interest. Our data indicate that the combination of improved internalization through specific targeting and radiosensitization using cetuximab-conjugated AuNPs is a promising strategy for increasing the eradication of cancer cells by protontherapy. Although the radiosensitization effect was initially attributed to a dose-enhancing mechanism, a growing number of studies are challenging this mechanistic hypothesis, highlighting the importance of chemical and biological contributions. Our work demonstrated that thioredoxin reductase revealed is a target for gold nanoparticles, disabling the antioxidant capacities of the cells and thus enhancing their sensitivity to proton irradiation.

Antibody-labeled gold nanoparticles also represent a promising new tool for cancer imaging. In order to translate the in vitro data, the biodistribution of the cetuximab-AuNP nanohybrids was studied in depth. To this end, the biodistribution of 89Zr-labeled cetuximab before and after coupling with AuNPs and injected into mice bearing xenografts showed that AuNPs coupled to 89Zr-cetuximab led to their specific accumulation in the tumor. 

In parallel, the cytotoxicity of AuNPs conjugated or not to cetuximab in normal human kidney (HK-2), liver (THLE-2) and microvascular endothelial (TIME) cells, the latter being the most sensitive. We also investigated the pharmacokinetics, biodistribution and toxicity after AuNP intravenous administration in healthy mice up to 6 months. These studies deepened the understanding of the risks associated with the use of AuNPs in vivo.

Altogether, our studies demonstrated that targeted radioisotope-labeled gold nanoparticles could be a promising theranostic agent for cancer.

Synthetic lethality and senolytic drugs in combination with radiotherapy

13/10/2026

Although improvements in radiation therapy were made over the years, radioresistance is still a major challenge. Cancer cells are often deficient for DNA repair response, a feature that is currently exploited as a new anti-cancer strategy. In this context, combination of inhibitors targeting complementary pathways is of interest to sensitize cells to radiation. In our work, combination of PARP and RAD51 inhibitors enhanced persistent DNA damage, delayed apoptosis, prolonged cell cycle arrest and senescence upon irradiation. Furthermore, they radiosensitized cancer cells to proton and X-ray irradiations in different cancer cell lines, an effect which correlated with cell proliferation rate.

Since we showed that treatment with irradiation with either photons or protons combined or not to PARP inhibitors induced senescence, the senescent cells were targeted by Navitoclax (ABT-263), a senolytic drug. An increase in the percentage of cell death was clearly obtained. Then, we determined how PARP inhibitors led to senescent cancer cells. We tested several PARP inhibitors: Veliparib, Rucaparib, Olaparib, Niraparib and Talazoparib. The results of our work demonstrated that Talazoparib induced the strongest phenotype of senescence in several cancer cell lines. These senescent cells could also be specifically targeted by senolytic to increase cell death. 

These results demonstrated that radiation-induced synthetic lethality, used alone or with senolytic drugs might widen the therapeutic window, hence extending the use of PARP inhibitors to patients without BRCAness.

Immunogenic cell death and radiotherapy: how to make them working together

27/10/2026

In response to radiotherapy, rare clinical cases have shown an abscopal effect, defined as the regression of tumors/metastases outside the irradiated field. The hypothesis is that this effect occurs through the induction of an antitumor immune response. The objective of our work is to determine whether protons would be able to induce greater antitumor immunity than that induced by X-rays in two syngeneic mouse cancer models. In vitro results showed the activation of the cGAS-STING pathway and type I IFN response after X-ray and proton irradiation. In addition, the expression of several immunosuppressive factors such as PD-L1, IL-10, IDO-1, and CD80/CD86 was increased after both types of irradiation. The mechanisms underlying PD-L1 overexpression were investigated since it may provide a way to stratify patients for immune checkpoint blocker therapy.

In addition, an in vivo vaccination trial demonstrated, in one of the two models (C3H/HeN syngeneic mouse model) but not in the other, an anti-tumor response induced by cancer cells irradiated with X-rays but not with protons. Depletion of CD8+ T cells abolished the antitumor response, highlighting the need for functional CD8+ T cells to trigger the systemic antitumor response induced by irradiation. These data highlight the potential benefits of using radiotherapy in combination with immunotherapy in the clinic to improve patient response to treatment.

Share this page